Dr. Peter Staats to Host Analyst Day on the Science Behind gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) on Tuesday, November 21, 2023
November 15 2023 - 8:15AM
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic
medicine and wellness company, announced today that the Company’s
Chief Medical Officer, Dr. Peter Staats will host an analyst day
entitled “Accessing the Power of Vagus Nerve Stimulation with
gammaCore™” on November 21, 2023 at 1:30pm EST. The webinar will
cover the nVNS mechanism of action and potential pipeline of
indications using the company’s proprietary nVNS technology
platform that is embodied in its gammaCore product.
Analyst Day: “Accessing the Power of Vagus Nerve
Stimulation with
gammaCore™”Date: Tuesday, November
21, 2023Time: 1:30pm – 2:30pm ESTRegistration:
https://electrocore.zoom.us/webinar/register/WN_wcHtB4caT--D58SYPiyryw
Participants interested in listening to the webinar can register
by clicking here. Following the live presentation, a playback of
the webinar will be available on the “Investors” section of the
company’s website at: www.electrocore.com.About
electroCore, Inc.electroCore, Inc. is a commercial stage
bioelectronic medicine and wellness company dedicated to improving
health through its nVNS technology platform. Our focus is the
commercialization of medical devices for the management and
treatment of certain medical conditions and consumer product
offerings utilizing nVNS to promote general wellbeing and human
performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Forward-Looking StatementsThis press release
and other written and oral statements made by representatives of
electroCore may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements include, but are not limited to,
statements about expectations for revenue for 2023 and beyond,
electroCore’s business prospects and clinical and product
development plans; its pipeline or potential markets for its
technologies; the timing, outcome and impact of regulatory,
clinical and commercial developments; business prospects around its
Truvaga wellness and TAC-STIM human performance offerings and other
new products and markets, and other statements that are not
historical in nature, particularly those that utilize terminology
such as "anticipates," "will," "expects," "believes," "intends,"
and other words of similar meaning, derivations of such words and
the use of future dates. Actual results could differ from those
projected in any forward-looking statements due to numerous
factors. Such factors include, among others, the ability to raise
the additional funding needed to continue to pursue electroCore’s
business and product development plans, the inherent uncertainties
associated with developing new products or technologies, the
ability to commercialize gammaCore™, TAC-STIM™, and Truvaga™, the
potential impact and effects of COVID-19 on the business of
electroCore, electroCore’s results of operations and financial
performance, inflation and currency fluctuations, and any
expectations electroCore may have with respect thereto, competition
in the industry in which electroCore operates and overall economic
and market conditions. Any forward-looking statements are made as
of the date of this press release, and electroCore assumes no
obligation to update the forward-looking statements or to update
the reasons why actual results could differ from those projected in
the forward-looking statements, except as required by law.
Investors should consult all of the information set forth herein
and should also refer to the risk factor disclosure set forth in
the reports and other documents electroCore files with the SEC
available at www.sec.gov.
Contact:ECOR Investor Relations(973)
302-9253investors@electrocore.com
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From Mar 2024 to Apr 2024
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From Apr 2023 to Apr 2024